Intense Prolonged Hypocalcemia and Hyperparathyroidism After Denosumab in Hemodialysis Patients in Response to the Published Article

Clinical Practice - United Kingdom
doi 10.4172/clinical-practice.100081
Full Text
Abstract

Available in full text

Date
Authors
Publisher

OMICS Publishing Group

Related search

Risk Factors for Severe Hypocalcemia After Parathyroidectomy in Dialysis Patients With Secondary Hyperparathyroidism

Scientific Reports
Multidisciplinary
2018English

Severe Hypocalcemia Due to Denosumab in Metastatic Prostate Cancer

Case Reports in Nephrology
2014English

Severe, Prolonged, Denosumab-Induced Hypocalcemia With Recovery After 111 Days of High Dose Calcium Supplementation: A Case Report

AACE Clinical Case Reports
2019English

Erratum To: Calcitriol Resistance in Hemodialysis Patients With Secondary Hyperparathyroidism

International Urology and Nephrology
UrologyNephrology
2014English

A Dramatic Response to Denosumab: Protracted Hypocalcemia Related to HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma

AACE Clinical Case Reports
2019English

Comparing the Values of Intact Parathormone and 1– 84 PTH to Predict Hyperparathyroidism in Hemodialysis Patients

Journal of Nephropathology
Nephrology
2017English

Effect of 22-Oxacalcitriol on Secondary Hyperparathyroidism in Hemodialysis Patients

Internal Medicine
Internal MedicineMedicine
2003English

Incidence of Hypocalcemia in Patients With Post-Menopausal Osteoporosis or Cancer Skeletal Related Events After Denosumab in Comparison to Zoledronic Acid in a Community Hospital Setting

Journal of Pharmacovigilance
2015English

Response to Dr. Livia Puljak’s Letter About Our Published Article

Journal of Clinical Epidemiology
Epidemiology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy